Schroder Investment Management Group
RYTM icon

Schroder Investment Management Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Schroder Investment Management Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
+131,674
New +$12.8M 0.01% 657
2025
Q4 		– Sell
-18,042
Closed -$1.82M – 1205
2025
Q3 		$1.82M Buy
18,042
+424
+2% +$39.4K ﹤0.01% 947
2025
Q2 		$1.11M Hold
17,618
– – ﹤0.01% 984
2025
Q1 		$965K Buy
+17,618
New +$977K ﹤0.01% 991

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Schroder Investment Management Group's RYTM Position: Q1 2026 in Review

Schroder Investment Management Group opened a new position in Rhythm Pharmaceuticals (RYTM) in Q1 2026: 131,674 shares worth $10.2M. The stake represents 0.01% of the portfolio and ranks #657 among its holdings. This is a return to the name: Schroder Investment Management Group previously reported a position in RYTM as recently as Q3 2025.

Schroder Investment Management Group first reported a position in RYTM in Q1 2025 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Schroder Investment Management Group held 131,674 shares of Rhythm Pharmaceuticals worth $10.2M as of Q1 2026.
  • Rhythm Pharmaceuticals was a new Schroder Investment Management Group position in Q1 2026.
  • Rhythm Pharmaceuticals made up 0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #657 holding.
  • Schroder Investment Management Group first reported a position in Rhythm Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.